X90.F PROBIOTIX HEALTH LS-05

Healthcare Biotechnology Frankfurt Exchange
0.1042 EUR
Close of Nov 12, 2026
0.0390 0.1020
Market cap
EUR 16.5M
P/E
-
P/B
6.85x
ROE
-85.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is X90.F undervalued?

Graham number

The Graham number of PROBIOTIX HEALTH LS-05 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PROBIOTIX HEALTH LS-05 fundamental analysis

No fundamental analysis for PROBIOTIX HEALTH LS-05 yet.

PROBIOTIX HEALTH LS-05 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PROBIOTIX HEALTH LS-05

ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and YourBiotixVH for vascular health support. The company was formerly known as ProB…

Full company profile